{"nctId":"NCT00717236","briefTitle":"Certolizumab Pegol for the Treatment of Patients With Active Rheumatoid Arthritis","startDateStruct":{"date":"2008-07"},"conditions":["Rheumatoid Arthritis"],"count":1648,"armGroups":[{"label":"Certolizumab pegol (CZP)","type":"EXPERIMENTAL","interventionNames":["Drug: Certolizumab pegol (CZP)"]},{"label":"Placebo","type":"PLACEBO_COMPARATOR","interventionNames":["Other: Placebo"]}],"interventions":[{"name":"Certolizumab pegol (CZP)","otherNames":["Cimzia"]},{"name":"Placebo","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Adult patient with established moderate to severe rheumatoid arthritis\n\nExclusion Criteria:\n\n* All concomitant diseases or pathological conditions that could interfere and impact the assessment of the study treatment\n* Previous clinical trials and previous biological therapy that could interfere with the results in the present clinical trials","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"American College of Rheumatology 20% (ACR20) Response at Week 12","description":"ACR20 responders are subjects with at least 20% improvement from Baseline for tender joint count (TJC), swollen joint count (SJC), and at least 3 of the 5 remaining core set measures: 1) Health Assessment Questionnaire-Disability Index (HAQ-DI), 2) C-reactive Protein (CRP), 3) Patient's Assessment of Arthritis Pain-Visual Analog Scale (PAAP-VAS), 4) Patient's Global Assessment of Disease Activity-Visual Analog Scale (PtGADA-VAS), 5) Physician's Global Assessment of Disease Activity-Visual Analog Scale (PhGADA-VAS)","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"51.1","spread":null},{"groupId":"OG001","value":"25.9","spread":null}]}]}]},{"type":"SECONDARY","title":"American College of Rheumatology 20% (ACR20) Response at Week 12 for Subjects With Concomitant Methotrexate (MTX) Use.","description":"ACR20 responders are subjects with at least 20% improvement from Baseline for tender joint count (TJC), swollen joint count (SJC), and at least 3 of the 5 remaining core set measures: 1) Health Assessment Questionnaire-Disability Index (HAQ-DI), 2) C-reactive Protein (CRP), 3) Patient's Assessment of Arthritis Pain-Visual Analog Scale (PAAP-VAS), 4) Patient's Global Assessment of Disease Activity-Visual Analog Scale (PtGADA-VAS), 5) Physician's Global Assessment of Disease Activity-Visual Analog Scale (PhGADA-VAS)","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"52.5","spread":null},{"groupId":"OG001","value":"28.0","spread":null}]}]}]},{"type":"SECONDARY","title":"American College of Rheumatology 20% (ACR20) Response at Week 12 for Subjects Without Concomitant Methotrexate (MTX) Use.","description":"ACR20 responders are subjects with at least 20% improvement from Baseline for tender joint count (TJC), swollen joint count (SJC), and at least 3 of the 5 remaining core set measures: 1) Health Assessment Questionnaire-Disability Index (HAQ-DI), 2) C-reactive Protein (CRP), 3) Patient's Assessment of Arthritis Pain-Visual Analog Scale (PAAP-VAS), 4) Patient's Global Assessment of Disease Activity-Visual Analog Scale (PtGADA-VAS), 5) Physician's Global Assessment of Disease Activity-Visual Analog Scale (PhGADA-VAS)","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"48.1","spread":null},{"groupId":"OG001","value":"21.7","spread":null}]}]}]},{"type":"SECONDARY","title":"American College of Rheumatology 20% (ACR20) Response at Week 12 for Subjects With Prior Anti-tumor Necrosis (Anti-TNF) Use","description":"ACR20 responders are subjects with at least 20% improvement from Baseline for tender joint count (TJC), swollen joint count (SJC), and at least 3 of the 5 remaining core set measures: 1) Health Assessment Questionnaire-Disability Index (HAQ-DI), 2) C-reactive Protein (CRP), 3) Patient's Assessment of Arthritis Pain-Visual Analog Scale (PAAP-VAS), 4) Patient's Global Assessment of Disease Activity-Visual Analog Scale (PtGADA-VAS), 5) Physician's Global Assessment of Disease Activity-Visual Analog Scale (PhGADA-VAS)","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"47.2","spread":null},{"groupId":"OG001","value":"27.5","spread":null}]}]}]},{"type":"SECONDARY","title":"American College of Rheumatology 20% (ACR20) Response at Week 12 for Subjects Without Prior Anti-tumor Necrosis (Anti-TNF) Use","description":"ACR20 responders are subjects with at least 20% improvement from Baseline for tender joint count (TJC), swollen joint count (SJC), and at least 3 of the 5 remaining core set measures: 1) Health Assessment Questionnaire-Disability Index (HAQ-DI), 2) C-reactive Protein (CRP), 3) Patient's Assessment of Arthritis Pain-Visual Analog Scale (PAAP-VAS), 4) Patient's Global Assessment of Disease Activity-Visual Analog Scale (PtGADA-VAS), 5) Physician's Global Assessment of Disease Activity-Visual Analog Scale (PhGADA-VAS)","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"53.5","spread":null},{"groupId":"OG001","value":"25.0","spread":null}]}]}]},{"type":"SECONDARY","title":"American College of Rheumatology 20% (ACR20) Response at Week 12 for Subjects With Disease Duration < 2 Years","description":"ACR20 responders are subjects with at least 20% improvement from Baseline for tender joint count (TJC), swollen joint count (SJC), and at least 3 of the 5 remaining core set measures: 1) Health Assessment Questionnaire-Disability Index (HAQ-DI), 2) C-reactive Protein (CRP), 3) Patient's Assessment of Arthritis Pain-Visual Analog Scale (PAAP-VAS), 4) Patient's Global Assessment of Disease Activity-Visual Analog Scale (PtGADA-VAS), 5) Physician's Global Assessment of Disease Activity-Visual Analog Scale (PhGADA-VAS)","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"50.0","spread":null},{"groupId":"OG001","value":"30.0","spread":null}]}]}]},{"type":"SECONDARY","title":"American College of Rheumatology 20% (ACR20) Response at Week 12 for Subjects With Disease Duration â‰¥ 2 Years.","description":"ACR20 responders are subjects with at least 20% improvement from Baseline for tender joint count (TJC), swollen joint count (SJC), and at least 3 of the 5 remaining core set measures: 1) Health Assessment Questionnaire-Disability Index (HAQ-DI), 2) C-reactive Protein (CRP), 3) Patient's Assessment of Arthritis Pain-Visual Analog Scale (PAAP-VAS), 4) Patient's Global Assessment of Disease Activity-Visual Analog Scale (PtGADA-VAS), 5) Physician's Global Assessment of Disease Activity-Visual Analog Scale (PhGADA-VAS)","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"51.5","spread":null},{"groupId":"OG001","value":"24.7","spread":null}]}]}]},{"type":"SECONDARY","title":"American College of Rheumatology 50% (ACR50) Response at Week 12","description":"ACR50 responders are subjects with at least 50% improvement from Baseline for tender joint count (TJC), swollen joint count (SJC), and at least 3 of the 5 remaining core set measures: 1) Health Assessment Questionnaire-Disability Index (HAQ-DI), 2) C-reactive Protein (CRP), 3) Patient's Assessment of Arthritis Pain-Visual Analog Scale (PAAP-VAS), 4) Patient's Global Assessment of Disease Activity-Visual Analog Scale (PtGADA-VAS), 5) Physician's Global Assessment of Disease Activity-Visual Analog Scale (PhGADA-VAS)","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"26.6","spread":null},{"groupId":"OG001","value":"9.9","spread":null}]}]}]},{"type":"SECONDARY","title":"American College of Rheumatology 70% (ACR70) Response at Week 12.","description":"ACR70 responders are subjects with at least 70% improvement from Baseline for tender joint count (TJC), swollen joint count (SJC), and at least 3 of the 5 remaining core set measures: 1) Health Assessment Questionnaire-Disability Index (HAQ-DI), 2) C-reactive Protein (CRP), 3) Patient's Assessment of Arthritis Pain-Visual Analog Scale (PAAP-VAS), 4) Patient's Global Assessment of Disease Activity-Visual Analog Scale (PtGADA-VAS), 5) Physician's Global Assessment of Disease Activity-Visual Analog Scale (PhGADA-VAS)","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"12.9","spread":null},{"groupId":"OG001","value":"2.8","spread":null}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in DAS28(CRP) [Disease Activity Score-28 (C-reactive Protein)] at Week 12","description":"DAS28(CRP) is calculated using tender joint count (TJC), swollen joint count (SJC), C-reactive protein (CRP in mg/L), and Patient's Global Assessment of Arthritis-Visual Analog Scale (PtGADA-VAS in mm). A lower score indicates less disease activity. Change from baseline is computed as Week 12 value minus baseline value. A negative value in change from baseline indicates an improvement. This analysis was carried out using the Last Observation Carried Forward (LOCF) method.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.70","spread":"1.269"},{"groupId":"OG001","value":"-0.84","spread":"1.209"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in SDAI (Simplified Disease Activity Index) at Week 12","description":"SDAI is calculated as the sum of tender joint count (TJC), swollen joint count (SJC), C-reactive protein (CRP in mg/dL), Patient's Global Assessment of Arthritis-Visual Analog Scale (PtGADA-VAS in cm), and Physician's Global Assessment of Disease Activity-Visual Analog Scale (PhGADA-VAS in cm). A lower score indicates less disease activity. Change from baseline is computed as Week 12 value minus baseline value. A negative value in change from baseline indicates an improvement. This analysis was carried out using the Last Observation Carried Forward (LOCF) method.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-19.66","spread":"14.493"},{"groupId":"OG001","value":"-10.78","spread":"15.172"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in CDAI (Clinical Disease Activity Index) at Week 12","description":"CDAI is calculated as the sum of tender joint count (TJC), swollen joint count (SJC), Patient's Global Assessment of Arthritis-Visual Analog Scale (PtGADA-VAS in cm), and Physician's Global Assessment of Disease Activity-Visual Analog Scale (PhGADA-VAS in cm). A lower score indicates less disease activity. Change from baseline is computed as Week 12 value minus baseline value. A negative value in change from baseline indicates an improvement. This analysis was carried out using the Last Observation Carried Forward (LOCF) method.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-18.96","spread":"14.019"},{"groupId":"OG001","value":"-10.93","spread":"14.494"}]}]}]},{"type":"SECONDARY","title":"DAS28(CRP) [Disease Activity Score-28 (C-reactive Protein)] Remission (<2.6) at Week 12","description":"DAS28(CRP) is calculated using tender joint count (TJC), swollen joint count (SJC), C-reactive protein (CRP in mg/L), and Patient's Global Assessment of Arthritis-Visual Analog Scale (PtGADA-VAS in mm). A lower score indicates less disease activity.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"16.0","spread":null},{"groupId":"OG001","value":"5.7","spread":null}]}]}]},{"type":"SECONDARY","title":"SDAI (Simplified Disease Activity Index) Remission (â‰¤3.3) at Week 12","description":"SDAI is calculated as the sum of tender joint count (TJC), swollen joint count (SJC), C-reactive protein (CRP in mg/dL), Patient's Global Assessment of Arthritis-Visual Analog Scale (PtGADA-VAS in cm), and Physician's Global Assessment of Disease Activity-Visual Analog Scale (PhGADA-VAS in cm). A lower score indicates less disease activity.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"7.8","spread":null},{"groupId":"OG001","value":"1.9","spread":null}]}]}]},{"type":"SECONDARY","title":"CDAI (Clinical Disease Activity Index) Remission (â‰¤2.8) at Week 12","description":"CDAI is calculated as the sum of tender joint count (TJC), swollen joint count (SJC), Patient's Global Assessment of Arthritis-Visual Analog Scale (PtGADA-VAS in cm), and Physician's Global Assessment of Disease Activity-Visual Analog Scale (PhGADA-VAS in cm). A lower score indicates less disease activity.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"8.3","spread":null},{"groupId":"OG001","value":"1.9","spread":null}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Tender Joint Count (TJC) at Week 12","description":"TJC is calculated based on tenderness response of 28 joints. TJC possible values range from 0 to 28. A lower TJC indicates less joint tenderness. Change from baseline is computed as Week 12 value minus baseline value. A negative value in change from baseline indicates an improvement. This analysis was carried out using the Last Observation Carried Forward (LOCF) method.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-7.4","spread":"7.13"},{"groupId":"OG001","value":"-4.5","spread":"7.38"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Swollen Joint Count (SJC) at Week 12","description":"SJC is calculated based on swelling response of 28 joints. SJC possible values range from 0 to 28. A lower SJC indicates less joint swelling. Change from baseline is computed as Week 12 value minus baseline value. A negative value in change from baseline indicates an improvement. This analysis was carried out using the Last Observation Carried Forward (LOCF) method.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-6.4","spread":"5.57"},{"groupId":"OG001","value":"-3.6","spread":"5.64"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Health Assessment Questionnaire-Disability Index (HAQ-DI) at Week 12","description":"HAQ-DI is derived based on the mean of individual scores in 8 categories of daily living actives (using 20 questions). Each question is scored 0-3 (0 = without any difficulty, 1 = with some difficulty, 2 = with much difficulty, and 3 = unable to do). Change from baseline is computed as Week 12 value minus baseline value. A negative value in change from baseline indicates an improvement. This analysis was carried out using the Last Observation Carried Forward (LOCF) method.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.38","spread":"0.524"},{"groupId":"OG001","value":"-0.19","spread":"0.507"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in C-reactive Protein (CRP) at Week 12","description":"Change from baseline in CRP (mg/L) is computed as the ratio of Week 12 value divided by baseline value. A ratio less then 1 indicates an improvement. This analysis was carried out using the Last Observation Carried Forward (LOCF) method.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.55","spread":"111.417"},{"groupId":"OG001","value":"1.05","spread":"89.633"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Patient's Assessment of Arthritis Pain-Visual Analog Scale (PAAP-VAS) at Week 12","description":"Change from Baseline in PAAP-VAS (0 to 100 mm visual analog scale, 0 being no pain and 100 being most severe pain) is computed as Week 12 value minus baseline value. A negative value in change from baseline indicates an improvement. This analysis was carried out using the Last Observation Carried Forward (LOCF) method.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-22.1","spread":"28.31"},{"groupId":"OG001","value":"-10.7","spread":"27.32"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Patient's Global Assessment of Disease Activity-Visual Analog Scale (PtGADA-VAS) at Week 12","description":"Change from Baseline in PtGADA-VAS (0 to 100 mm visual analog scale, 0 being no symptoms and 100 being severe symptoms) is computed as Week 12 value minus baseline value. A negative value in change from baseline indicates an improvement. This analysis was carried out using the Last Observation Carried Forward (LOCF) method.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-21.5","spread":"27.78"},{"groupId":"OG001","value":"-10.1","spread":"26.24"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Physician's Global Assessment of Disease Activity-Visual Analog Scale (PhGADA-VAS) at Week 12","description":"Change from Baseline in PhGADA-VAS (0 to 100 mm visual analog scale, 0 being no symptoms and 100 being severe symptoms) is computed as Week 12 value minus baseline value. A negative value in change from baseline indicates an improvement. This analysis was carried out using the Last Observation Carried Forward (LOCF) method.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-31.2","spread":"23.58"},{"groupId":"OG001","value":"-19.0","spread":"25.15"}]}]}]},{"type":"SECONDARY","title":"Time to Sustained American College of Rheumatology 20% (ACR20) Response","description":"The time from randomization to sustained ACR20 response at 2 consecutive visits (at the latest on Week 12).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"40.4","spread":null},{"groupId":"OG001","value":"13.2","spread":null}]}]}]},{"type":"SECONDARY","title":"European League Against Rheumatism (EULAR) Response at Week 12","description":"EULAR response (good response, moderate response, or no response) is defined based on the present value and improvement from baseline in DAS28(CRP) \\[Disease Activity Score-28 (C-reactive protein)\\].","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"28.9","spread":null},{"groupId":"OG001","value":"10.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"44.5","spread":null},{"groupId":"OG001","value":"37.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"26.6","spread":null},{"groupId":"OG001","value":"52.4","spread":null}]}]}]},{"type":"SECONDARY","title":"American College of Rheumatology 20% (ACR20) Response at Week 28","description":"ACR20 responders are subjects with at least 20% improvement from Baseline for tender joint count (TJC), swollen joint count (SJC), and at least 3 of the 5 remaining core set measures: 1) Health Assessment Questionnaire-Disability Index (HAQ-DI), 2) C-reactive Protein (CRP), 3) Patient's Assessment of Arthritis Pain-Visual Analog Scale (PAAP-VAS), 4) Patient's Global Assessment of Disease Activity-Visual Analog Scale (PtGADA-VAS), 5) Physician's Global Assessment of Disease Activity-Visual Analog Scale (PhGADA-VAS). This analysis was carried out using imputation.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"58.5","spread":null}]}]}]},{"type":"SECONDARY","title":"American College of Rheumatology 50% (ACR50) Response at Week 28","description":"ACR50 responders are subjects with at least 50% improvement from Baseline for tender joint count (TJC), swollen joint count (SJC), and at least 3 of the 5 remaining core set measures: 1) Health Assessment Questionnaire-Disability Index (HAQ-DI), 2) C-reactive Protein (CRP), 3) Patient's Assessment of Arthritis Pain-Visual Analog Scale (PAAP-VAS), 4) Patient's Global Assessment of Disease Activity-Visual Analog Scale (PtGADA-VAS), 5) Physician's Global Assessment of Disease Activity-Visual Analog Scale (PhGADA-VAS). This analysis was carried out using imputation.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"35.0","spread":null}]}]}]},{"type":"SECONDARY","title":"American College of Rheumatology 70% (ACR70) Response at Week 28","description":"ACR70 responders are subjects with at least 70% improvement from Baseline for tender joint count (TJC), swollen joint count (SJC), and at least 3 of the 5 remaining core set measures: 1) Health Assessment Questionnaire-Disability Index (HAQ-DI), 2) C-reactive Protein (CRP), 3) Patient's Assessment of Arthritis Pain-Visual Analog Scale (PAAP-VAS), 4) Patient's Global Assessment of Disease Activity-Visual Analog Scale (PtGADA-VAS), 5) Physician's Global Assessment of Disease Activity-Visual Analog Scale (PhGADA-VAS). This analysis was carried out using imputation.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"17.4","spread":null}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in DAS28(CRP) [Disease Activity Score-28 (C-reactive Protein)] at Week 28","description":"DAS28(CRP) is calculated using tender joint count (TJC), swollen joint count (SJC), C-reactive protein (CRP in mg/L), and Patient's Global Assessment of Arthritis-Visual Analog Scale (PtGADA-VAS in mm). A lower score indicates less disease activity. Change from Baseline is computed as the value at Week 28 minus Baseline value. A negative value in change from Baseline indicates an improvement. This analysis was done using a Mixed Effects Repeated Measures Model (MMRM).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.94","spread":"0.055"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in SDAI (Simplified Disease Activity Index) at Week 28","description":"SDAI is calculated as the sum of tender joint count (TJC), swollen joint count (SJC), C-reactive protein (CRP in mg/dL), Patient's Global Assessment of Arthritis-Visual Analog Scale (PtGADA-VAS in cm), and Physician's Global Assessment of Disease Activity-Visual Analog Scale (PhGADA-VAS in cm). A lower score indicates less disease activity. Change from Baseline is computed as the value at Week 28 minus the Baseline value. A negative value in change from Baseline indicates an improvement. This analysis was done using a Mixed Effects Repeated Measures Model (MMRM).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-22.35","spread":"0.546"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in CDAI (Clinical Disease Activity Index) at Week 28","description":"CDAI is calculated as the sum of tender joint count (TJC), swollen joint count (SJC), Patient's Global Assessment of Arthritis-Visual Analog Scale (PtGADA-VAS in cm), and Physician's Global Assessment of Disease Activity-Visual Analog Scale (PhGADA-VAS in cm). A lower score indicates less disease activity. Change from Baseline is computed as value at Week 28 minus the Baseline value. A negative value in change from Baseline indicates an improvement. This analysis was done using a Mixed Effects Repeated Measures Model (MMRM).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-21.66","spread":"0.533"}]}]}]},{"type":"SECONDARY","title":"DAS28(CRP) [Disease Activity Score-28 (C-reactive Protein)] Remission (<2.6) at Week 28","description":"DAS28(CRP) is calculated using tender joint count (TJC), swollen joint count (SJC), C-reactive protein (CRP in mg/L), and Patient's Global Assessment of Arthritis-Visual Analog Scale (PtGADA-VAS in mm). A lower score indicates less disease activity. This analysis was carried out using imputation.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"22.6","spread":null}]}]}]},{"type":"SECONDARY","title":"SDAI (Simplified Disease Activity Index) Remission (â‰¤3.3) at Week 28","description":"SDAI is calculated as the sum of tender joint count (TJC), swollen joint count (SJC), C-reactive protein (CRP in mg/dL), Patient's Global Assessment of Arthritis-Visual Analog Scale (PtGADA-VAS in cm), and Physician's Global Assessment of Disease Activity-Visual Analog Scale (PhGADA-VAS in cm). A lower score indicates less disease activity. This analysis was carried out using imputation.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"11.4","spread":null}]}]}]},{"type":"SECONDARY","title":"CDAI (Clinical Disease Activity Index) Remission (â‰¤2.8) at Week 28","description":"CDAI is calculated as the sum of tender joint count (TJC), swollen joint count (SJC), Patient's Global Assessment of Arthritis-Visual Analog Scale (PtGADA-VAS in cm), and Physician's Global Assessment of Disease Activity-Visual Analog Scale (PhGADA-VAS in cm). A lower score indicates less disease activity. This analysis was carried out using imputation.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"12.1","spread":null}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Tender Joint Count (TJC) at Week 28","description":"TJC is calculated based on tenderness response of 28 joints. TJC possible values range from 0 to 28. A lower TJC indicates less joint tenderness. Change from Baseline is computed as the value at Week 28 minus the Baseline value. A negative value in change from Baseline indicates an improvement. This analysis was done using a Mixed Effects Repeated Measures Model (MMRM).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-8.6","spread":"0.26"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Swollen Joint Count (SJC) at Week 28","description":"SJC is calculated based on swelling response of 28 joints. SJC possible values range from 0 to 28. A lower SJC indicates less joint swelling. Change from baseline is computed as the value at Week 28 minus the baseline value. A negative value in change from baseline indicates an improvement. This analysis was done using a Mixed Effects Repeated Measures Model (MMRM).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-7.2","spread":"0.19"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Health Assessment Questionnaire-Disability Index (HAQ-DI) at Week 28","description":"HAQ-DI is derived based on the mean of individual scores in 8 categories of daily living actives (using 20 questions). Each question is scored 0-3 (0 = without any difficulty, 1 = with some difficulty, 2 = with much difficulty, and 3 = unable to do). Change from baseline is computed as the value at Week 28 minus the baseline value. A negative value in change from baseline indicates an improvement. This analysis was done using a Mixed Effects Repeated Measures Model (MMRM).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.46","spread":"0.023"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in C-reactive Protein (CRP) at Week 28","description":"Change from Baseline in CRP (mg/L) is computed as the ratio of the value at Week 28 divided by Baseline value. A ratio less then 1 indicates an improvement. This analysis was done using a Mixed Effects Repeated Measures Model (MMRM).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.59","spread":"122.929"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Patient's Assessment of Arthritis Pain-Visual Analog Scale (PAAP-VAS) at Week 28","description":"Change from Baseline in PAAP-VAS (0 to 100 mm visual analog scale, 0 being no pain and 100 being most severe pain) is computed as the value at Week 28 minus the Baseline value. A negative value in change from Baseline indicates an improvement. This analysis was done using a Mixed Effects Repeated Measures Model (MMRM).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-23.1","spread":"1.06"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Patient's Global Assessment of Disease Activity-Visual Analog Scale (PtGADA-VAS) at Week 28","description":"Change from Baseline in PtGADA-VAS (0 to 100 mm visual analog scale, 0 being no symptoms and 100 being severe symptoms) is computed as the value at Week 28 minus the Baseline value. A negative value in change from Baseline indicates an improvement. This analysis was done using a Mixed Effects Repeated Measures Model (MMRM).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-23.0","spread":"1.04"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Physician's Global Assessment of Disease Activity-Visual Analog Scale (PhGADA-VAS) at Week 28","description":"Change from Baseline in PhGADA-VAS (0 to 100 mm visual analog scale, 0 being no symptoms and 100 being severe symptoms) is computed as the value at Week 28 minus the Baseline value. A negative value in change from Baseline indicates an improvement. This analysis was done using a Mixed Effects Repeated Measures Model (MMRM).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-35.6","spread":"0.85"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":52,"n":846},"commonTop":["Upper respiratory tract infection","Rheumatoid Arthritis","Urinary Tract Infection","Headache","Nasopharyngitis"]}}}